Long-term prevention of diabetic nephropathy: An audit

Diabetologia

Volumn 51, Issue 6, 2008, Pages 956-961

  Schjoedt, K J ^a   Hansen, H P ^a   Tarnow, L ^a   Rossing, P ^a   Parving, H H ^b,c  

^a STENO DIABETES CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

ACE inhibitors; Angiotensin II receptor blockers; Audit; Diabetic nephropathy; Microalbuminuria; Prevention; RAAS blockade; Renin angiotensin aldosterone system; Renoprotection; Type 1 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MICROALBUMINURIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICAL AUDIT; MIDDLE AGED; STROKE; SURVIVAL ANALYSIS;

EID: 43049129230     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-0990-3     Document Type: Article

References (31)

1. Parving H-H, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 100:550-555
2. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430-1432
3. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93
4. Mathiesen ER, Oxenbøll B, Johansen K, Svendsen PA, Deckert T (1984) Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 26:406-410
5. Feldt-Rasmussen B, Mathiesen ER, Deckert T (1986) Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet ii:1300-1304
6. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297:1092-1095
7. Mathiesen ER, Hommel E, Giese J, Parving H-H (1991) Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. BMJ 303:81-87
8. Bangstad H-J, Østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37:483-490
9. The Microalbuminuria Captopril Study Group (1996) Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39:587-593
10. Crepaldi G, Carta Q, Deferrari G et al (1998) Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 21:104-110
11. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H-H (1999) Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319:24-25
12. Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group (1994) Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279
13. Laffel LMB, McGill JB, Gans JD (1995) The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-504
14. The Euclid Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792
15. The ACE Inhibitors in Diabetic Nephropathy Trialist Group (2001) Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 134:370-379
16. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
17. Mogensen CE, Keane WF, Bennett PH et al (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084
18. Hansen HP, Lund SS, Rossing P et al (2001) Preventing diabetic nephropathy: an audit. Scand J Clin Lab Invest 61:471-477
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
20. Rossing P, Hougaard P, Parving H-H (2005) Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 68:1446-1450
21. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Hansen PR, Parving H-H (2005) Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250-1257
22. Forsblom CM, Groop P-H, Ekstrand A, Groop L (1992) Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 305:1051-1053
23. Giorgino F, Laviola L, Cavallo PP, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028
24. Almdal T, Nørgaard K, Feldt-Rasmussen B, Deckert T (1994) The predictive value of microalbuminuria in IDDM. Diabetes Care 17:120-125
25. Warram JH, Scott LJ, Hanna LS et al (2000) Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49:94-100
26. Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M (1993) Comparison of reduction in microalbuminuria by enalapril and hydrochlorthiazide in normotensive patients with insulin dependent diabetes. BMJ 306:175-182
27. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. BMJ 313:779-784
28. de Zeeuw D, Remuzzi G, Parving H-H et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921-927
29. de Zeeuw D, Remuzzi G, Parving H-H et al (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65:2309-2320
30. Ibsen H, Olsen MH, Wachtell K et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198-202
31. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497